Research led by a Houston Methodist gastroenterologist shows that patients who have inflammatory bowel disease (IBD) for more than two decades have a higher risk of
developing nonalcoholic fatty liver disease (NAFLD).
Not exact matches
Cirius Therapeutics, a clinical - stage pharmaceutical company, is
developing MSDC - 0602K, a next - generation insulin sensitizer for the treatment of
nonalcoholic steatohepatitis (NASH).
Nonalcoholic fatty liver disease (NAFLD)-- induced hepatocellular carcinoma (HCC) is an emerging malignancy in the
developed world; however, mechanisms that contribute to its formation are largely unknown, and targeted therapy is currently not available.
«Understanding how maternal exposures impact obesity - related disease such as
nonalcoholic fatty liver disease will allow us to
develop lower cost preventative therapies to utilize up front rather than awaiting complications down the road.»
«However, only a smaller number of these individuals will
develop the most severe form of this disease known as
nonalcoholic steatohepatitis or NASH.»
Spurlock's binge placed him at risk for
developing a syndrome called
nonalcoholic steatohepatitis, or NASH.
Roughly one - quarter of Americans — an estimated 100 million adults and children — have NAFLD, which can progress to a more serious form called
nonalcoholic steatohepatitis, which in turn can
develop into cirrhosis, liver cancer and liver failure.